Key result
Female sex is linked to ~57% fewer complications and deaths after tricuspid TEER vs. males.
Why the study?
Severe tricuspid regurgitation has limited treatment options and high perioperative risk limits surgical intervention, creating demand for minimally invasive alternatives like T-TEER.
Observational (n=1,960)
Yes
Odds Ratio: 0.43 (95% CI 0.23–0.83)
T-TEER utilization is increasing with decreasing length of hospital stay, though complex comorbidities predict higher complication rates and females have lower mortality and complications than males.
T-TEER may aid high-risk severe TR management post-FDA approval; leaves open need for RCTs on long-term outcomes.
Background Severe tricuspid regurgitation (TR) is associated with significant morbidity and mortality and has limited treatment options. Surgical intervention is often contraindicated due to high perioperative risk, creating a demand for minimally invasive alternatives like tricuspid transcatheter edge‐to‐edge repair (T‐TEER). The FDA approval of the TriClip G4 System in April 2024 marked a pivotal advancement in TR management. Objective This study analyzed trends, outcomes, and predictors associated with T‐TEER placement using the National Inpatient Sample database from 2018 to 2021. Methods A retrospective analysis was conducted on 1960 patients undergoing T‐TEER identified via ICD‐10‐CM coding. Patient demographics, comorbidities, procedural complications, in‐hospital mortality, length of stay, and hospitalization costs were analyzed using logistic regression models. Key outcomes included trends in procedural volume, mortality, complications, and economic impact. Results Over the study period, T‐TEER procedures increased significantly, with improved outcomes and reduced hospital stays. Female patients experienced lower mortality and complications compared to males (OR 0.43, 95% CI 0.23–0.83). Patients with comorbidities, including pulmonary hypertension, liver disease, and peripheral vascular disease, demonstrated higher complication rates. Length of hospital stay decreased from three days in 2018–2019 to two days in 2019–2021, while median hospitalization costs remained high, particularly for patients with congestive heart failure and coagulopathy. Conclusions T‐TEER offers a viable alternative for patients with high‐risk TR, with increasing utilization and subsequent decrease in procedural complications over time. While our study highlights some disparities in outcomes among patients with complex comorbidities, further studies are warranted to assess long‐term procedural efficacy, safety, and outcomes.
No takes yet. Share an insight, caveat, or question.
Nassar et al. (2026) conducted an observational in Severe tricuspid regurgitation (TR) (n=1,960). Tricuspid transcatheter edge-to-edge repair (T-TEER) was evaluated on Mortality and complications (female vs. male) (OR 0.43, 95% CI 0.23-0.83). Among patients undergoing tricuspid transcatheter edge-to-edge repair, female sex was associated with lower mortality and complications compared to males (OR 0.43; 95% CI 0.23-0.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: